April 16 (Reuters) - AstraZeneca PLC:
* UPDATED OVERALL SURVIVAL DATA FOR LYNPARZA IN BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTED AT AACR
* LYNPARZA TRIAL MET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL
* RESULTS AT AACR INCLUDE UPDATED FINDINGS FROM SECONDARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage: